Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 3/20 | 0.58 |
| ▸ | GSK3B | P49841 | 2/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 6/20 | 0.56 |
| ▸ | JAK1 | P23458 | 5/20 | 0.56 |
| ▸ | JAK3 | P52333 | 9/20 | 0.55 |
| ▸ | TYK2 | P29597 | 4/20 | 0.55 |
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | CKS1B | P61024 | 1/20 | 0.52 |
| ▸ | SKP1 | P63208 | 1/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.52 |
| ▸ | ACACB | O00763 | 1/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30151471 | 1.00 | AKT2 (0.58) | AKT2GSK3BLCKJAK2JAK1 | |
| SCHEMBL13651711 | 0.88 | JAK3 (0.57) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL1005506 | 0.85 | KIT (0.60) | AKT2GSK3BLCKJAK2JAK1 | |
| SCHEMBL30151464 | 0.85 | KIT (0.60) | AKT2GSK3BLCKJAK2JAK1 | |
| SCHEMBL4124792 | 0.84 | SIRT2 (0.52) | AKT2JAK2JAK1KITCKS1B | |
| SCHEMBL14391712 | 0.84 | AKT2 (0.58) | AKT2CKS1BSKP1SKP2SIRT2 | |
| SCHEMBL14162955 | 0.83 | JAK3 (0.49) | AKT2JAK2JAK1JAK3 | |
| SCHEMBL24805277 | 0.82 | AKT1 (0.53) | CKS1BSKP1SKP2SIRT2SIRT1 | |
| SCHEMBL24804209 | 0.82 | LCK (0.55) | AKT2GSK3BLCKJAK2JAK1 | |
| SCHEMBL24805941 | 0.82 | ENPP1 (0.64) | AKT2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411420-A1 | PYRROLOPYRIMIDINE DERIVATIVE HAVING ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE INHIBITORY ACTIVITY AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-12-29 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| WO-2007125315-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253718-A1 | Pharmaceutical Compounds | GRK3, CNKSR1, CSNK1G3 | AKT2 153/4885GSK3B 157/4885LCK 726/4885 |
| US-20220411420-A1 | PYRROLOPYRIMIDINE DERIVATIVE HAVING ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE INHIBITORY ACTIVITY AND USE THEREOF | ENPP1, ENPP3, PPA1 | AKT2 1623/4885GSK3B 942/4885LCK 2213/4885 |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | OXSR1, CDK1, CDK3 | AKT2 999/4885GSK3B 605/4885LCK 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.